The company is also developing a similar version of Detach® to prevent diarrhoea in humans.
The prevention and treatment of diarrhoea in humans is a significant unmet market opportunity, with no product available to prevent this disease. The diversity of different causes of diarrhoea makes it difficult for drug developers to find a solution.
With millions of international travellers around the world, many are at risk of developing diarrhoea, leading to the disruption of holiday plans and business.
Diarrhoea is also a threat to military capabilities when troops are deployed overseas. Therefore the development of effective preventatives is a priority for the US Army.
Children are also very susceptible to diarrhoeal disease, with the World Health Organisation identifying it as the second leading cause of death in children under five years of age. There are nearly 1.7 billion cases of diarrhoea every year leading to nearly 1 million deaths.
Detach® may also be used in areas where seasonality of diarrhoea is common, or at times of acute diarrhoea outbreaks where water sanitation has failed or following natural disasters, such as flooding.
Phase I clinical trials in humans have been conducted and further clinical development is planned, should a suitable partner be identified.